Novartis (NVS) can be of some help from the Ivy League when it comes to getting U.S. approval for its new meningitis vaccine .
Princeton University was borbavspyshka meningitis B- strain does not apply to conventional vaccination protocols available in the U.S. , which has infected at least seven students in March , with the latest victim was hospitalized earlier this month. Now the school has decided to allow students to receive injections of vaccine Novartis, which has been approved in the European Union and Australia, but not by the U.S. Food and Drug Administration .
Novartis and FDA officials " have not yet come to an agreement oputi licensing " for Bexsero, said Liz Power , Press sekretarshveytsarskoy pharmaceuticals . The U.S. Centers for Disease Control and Prevention received permission last week sFDA to import the vaccine because of a new outbreak of Jersey .
Graphics: Innovation: The cancer vaccine Irving Weissman of Stanford
Princeton will be the first of two doses of vaccine ready in early December , with the second sale in February , two doses are needed for maximum protection , the school said in a statement: "Students who have already poluchilimeningokokkovoy vaccine is not currently protected against serogroup , bacteria, vyzyvayuschihvspyshki in Princeton. "The university has said it will pay the costs of the vaccine for students who want to receive it.
Bacterial meningitis is an inflammation of the lining around the brain and spinal cord , with symptoms that include fever , headache , vomiting , pain in the neck, and sensitivity to light . Meningitis is transmitted through saliva and other close contact , such as kissing and sharing drinking glasses .
Pfizer (PFE) is also conducting trials on a vaccine for the strain Bbaktery . Additional strains are generally considered vaccines on the market but version B is more complex chemical, and was difficult to attack. B type of the disease was more common in Australia and Europe than in the U.S.
Power said the company could not speculate on how the limited use of Bexsero at Princeton may affect the approval process for the vaccine with the FDA.